Kyverna Therapeutics Inc (KYTX)

$2.13 +0.03 (1.43%)
Market Cap 90.76M
Revenue (ttm) 0.00
Net Income (ttm) -127.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 227,500
Avg Vol 298,178
Day's Range N/A - N/A
Shares Out 43.22M
Stochastic %K 71%
Beta 2.57
Analysts Strong Sell
Price Target $19.14

Latest News on KYTX

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 4:02 PM EDT - 27 days ago

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Mar 21, 2025, 11:29 AM EDT - 4 weeks ago

Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Mar 3, 2025, 4:05 PM EST - 7 weeks ago

Kyverna Therapeutics to Present at the Leerink Partners Global Biopharma Conference

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Feb 7, 2025, 11:42 AM EST - 2 months ago

KYTX Deadline: KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

Feb 6, 2025, 1:51 PM EST - 2 months ago

Investors in Kyverna Therapeutics, Inc. Should Contact The Gross Law Firm Before February 7, 2025 to Discuss Your Rights – KYTX

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Feb 5, 2025, 11:54 AM EST - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

Feb 4, 2025, 3:51 AM EST - 2 months ago

Final Deadline for the Kyverna Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - KYTX

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Jan 27, 2025, 3:22 PM EST - 3 months ago

KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Lawsuit

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Jan 21, 2025, 4:05 PM EST - 3 months ago

Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 7:30 AM EST - 3 months ago

Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

Jan 6, 2025, 4:05 PM EST - 3 months ago

Kyverna Therapeutics to Present at the 43rd Annual J. P. Morgan Healthcare Conference

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics

Dec 24, 2024, 8:10 AM EST - 4 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics